All Episodes
|
208
|
Dr. Michael Chernew

The Affordability Crisis Behind Value-Based Care w/ Dr. Michael Chernew, Harvard

Jun 12, 2026

Episode Summary

U.S. health care spending keeps rising, quality scores keep climbing, and yet the care most Americans receive has barely improved. The measurement systems designed to drive better outcomes may be making things worse.Dr. Michael Chernew, Professor of Health Care Policy at Harvard Medical School and former Chair of MedPAC, joins host John Marchica to examine why decades of quality measurement have failed to move the needle on actual care quality, and whether value-based payment models can survive the incentive distortions they were built to fix.

Episode Notes

U.S. health care spending keeps rising, quality scores keep climbing, and yet the care most Americans receive has barely improved. The measurement systems designed to drive better outcomes may be making things worse.

Dr. Michael Chernew, Professor of Health Care Policy at Harvard Medical School and former Chair of MedPAC, joins host John Marchica to examine why decades of quality measurement have failed to move the needle on actual care quality, and whether value-based payment models can survive the incentive distortions they were built to fix.

================================================

🎙 ABOUT DR. MICHAEL CHERNEW
Michael Chernew, PhD, is the Leonard D. Schaeffer Professor of Health Care Policy and Director of the Health care Markets and Regulation (HMR) Lab at Harvard Medical School. His research focuses on improving the health care system through novel benefit designs, Medicare Advantage, alternative payment models, low-value care, and rising health care spending. Dr. Chernew currently chairs the Medicare Payment Advisory Commission (MedPAC), having previously served as vice chair (2012–2014) and member (2008–2012), and has thrice served on CMS technical advisory panels (2000, 2004, 2010) reviewing Medicare trust fund financial assumptions. Additionally, he is a member of the CBO’s Panel of Health Advisors, Vice Chair of the Massachusetts Health Connector Board, a member of the National Academy of Sciences, a research associate at the National Bureau of Economic Research, a senior Visiting Fellow at MITRE, and co-editor of the American Journal of Managed Care. He earned his undergraduate degree from the University of Pennsylvania and a PhD in economics from Stanford University, and was awarded both the John D. Thompson Prize (1998) and the Alice S. Hersh Young Investigator Award (1999).

🎙 ABOUT HEALTH CARE ROUNDS
Health Care Rounds is a weekly podcast developed for health care leaders who are at the forefront of health care delivery and payment reform. Join Darwin Research Group founder and CEO John Marchica as he discusses the latest advancements in health care business news and policy developments.  

================================================

CONNECT WITH US:

🌐 Visit us on the web

🌐 Follow Health Care Rounds on LinkedIn

🌐 Follow Darwin Research Group on LinkedIn

📺 Watch Health Care Rounds on YouTube

🎧 Listen on Apple Podcasts

🎧 Listen on Spotify

⚙️ Health Care Rounds is produced by Grippi Media

Recommended Next

Why Nobody is Winning The Payer-Provider AI Arms Race w/ Dr. Marc Harrison, TowerBrook Healthcare Institute
Mailbag: Virtual Nurses, Bundled Payments, and Single Payer
When MisInformation Becomes a Health Crisis w/ Dr. Joshua Sharfstein, Johns Hopkins
Real Health Care Happens Between Doctor Visits w/ Wei-Li Shao, President, Omada Health
Mailbag: Debunking Vaccines Myths
Health Care's Affordability Crisis Is Getting Worse w/ Larry Levitt, CEO-Elect & EVP, KFF
Are We Measuring Health Care Quality All Wrong? w/ Dr. Rachel Werner, Professor of Medicine, UPenn
The State of Value-Based Health Care w/ John Marchica, Darwin Research Group

Recommended Content

Browse Library
INsights
September 14, 2026

OpenAI announces integration of ChatGPT for Healthcare with Epic’s EHR

Read More
INsights
August 31, 2026

FDA grants momentous approval in pancreatic cancer

Read More
INsights
August 24, 2026

Moderna, Merck announce positive Phase III trial results for personalized mRNA cancer therapy

Read More
Stay Aware. Stay Informed.

Subscribe to Our Take

Sign up for Our Take Newsletter: highly curated, expert weekly strategic insights for health care executives.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.